Jazz Pharmaceuticals JAZZ Pre-Tax Income (Domestic)
Pre-Tax Income (Domestic) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's pre-tax income (domestic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's pre-tax income (domestic)?
- Jazz Pharmaceuticals (JAZZ) reported pre-tax income (domestic) of $41.17M in Q4 2025.
- How has Jazz Pharmaceuticals's pre-tax income (domestic) changed year-over-year?
- Jazz Pharmaceuticals's pre-tax income (domestic) decreased by 66.9% year-over-year, from $124.47M to $41.17M.
- What is the long-term trend for Jazz Pharmaceuticals's pre-tax income (domestic)?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's pre-tax income (domestic) has grown at a 14.0% compound annual growth rate (CAGR), from $97.56M to $164.7M.
- What does pre-tax income (domestic) mean?
- The profit or loss from domestic business activities before taxes.
- How do you interpret pre-tax income (domestic)?
- Higher domestic pre-tax income indicates strong core performance within the home market.
- How does pre-tax income (domestic) compare across companies?
- Standard geographic segment reporting; essential for analyzing tax jurisdiction performance.